Kali, Inc. (OTC:KALY) d.b.a. Kali-Extracts, Inc. is comprised of two distinct divisions: cannabinoid pharmaceuticals and cannabis extracts/concentrates. On November 15th, 2018, KALY acquired NCM Biotech to include a patented cannabis extraction process and associated intellectual properties consisting of years of preclinical research studies surrounding a multitude of applications of cannabis extracts derived from the patented cannabis extraction process. The acquired cannabis biotechnology intellectual properties will be contained within the new Kali Cannabis Therapies subsidiary were ongoing research and development will be conducted for the purposes of producing cannabis treatments for specific conditions.
Also, Kali, Inc. has entered into a joint venture agreement named US Cannabis Health with Puration, Inc. (OTC:PURA), and Nouveau Pharmaceuticals, Inc. (OTC:NOUV) to combine their respective resources for the specific purpose of developing partnerships with major pharmaceutical companies to produce medical cannabis therapies.